{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T21:27:31Z","timestamp":1771104451616,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,31]]},"DOI":"10.7759\/cureus.68337","type":"journal-article","created":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T02:55:50Z","timestamp":1725159350000},"source":"Crossref","is-referenced-by-count":2,"title":["Longitudinally Extensive Transverse Myelitis in a Patient With Systemic Lupus Erythematosus: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Prakash","family":"Banjade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudip","family":"Bastakoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashmita","family":"Poudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1001112","article-title":"Clinical practice. Transverse myelitis","volume":"363","author":"Frohman EM","year":"2010","unstructured":"Frohman EM, Wingerchuk DM. Clinical practice. Transverse myelitis. N Engl J Med. 2010, 363:564-72. 10.1056\/NEJMcp1001112","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2014.11.014","article-title":"Longitudinally extensive transverse myelitis in systemic lupus erythematosus: case report and review of the literature","volume":"129","author":"Nardone R","year":"2015","unstructured":"Nardone R, Fitzgerald RT, Bailey A, Zuccoli G. Longitudinally extensive transverse myelitis in systemic lupus erythematosus: case report and review of the literature. Clin Neurol Neurosurg. 2015, 129:57-61. 10.1016\/j.clineuro.2014.11.014","journal-title":"Clin Neurol Neurosurg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1743211","article-title":"Longitudinally extensive transverse myelitis: one disease, variable outcomes-a case series","volume":"13","author":"Chandrasekar S","year":"2022","unstructured":"Chandrasekar S, John J, Satapathy AK. Longitudinally extensive transverse myelitis: one disease, variable outcomes-a case series. J Neurosci Rural Pract. 2022, 13:339-42. 10.1055\/s-0042-1743211","journal-title":"J Neurosci Rural Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.2.120","article-title":"Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature","volume":"59","author":"Kovacs B","year":"2000","unstructured":"Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. 2000, 59:120-4. 10.1136\/ard.59.2.120","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2017.06.003","article-title":"Myelitis in systemic lupus erythematosus","volume":"44","author":"Li XY","year":"2017","unstructured":"Li XY, Xiao HB, Pai P. Myelitis in systemic lupus erythematosus. J Clin Neurosci. 2017, 44:18-22. 10.1016\/j.jocn.2017.06.003","journal-title":"J Clin Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2012.09.008","article-title":"Transverse myelitis","volume":"31","author":"Beh SC","year":"2013","unstructured":"Beh SC, Greenberg BM, Frohman T, Frohman EM. Transverse myelitis. Neurol Clin. 2013, 31:79-138. 10.1016\/j.ncl.2012.09.008","journal-title":"Neurol Clin"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1019132","article-title":"An approach to the diagnosis of acute transverse myelitis","volume":"28","author":"Jacob A","year":"2008","unstructured":"Jacob A, Weinshenker BG. An approach to the diagnosis of acute transverse myelitis. Semin Neurol. 2008, 28:105-20. 10.1055\/s-2007-1019132","journal-title":"Semin Neurol"},{"key":"ref8","unstructured":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. (1999). Accessed. August 31, 2024: https:\/\/pubmed.ncbi.nlm.nih.gov\/10211873\/."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.106351","article-title":"Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus","volume":"69","author":"Hanly JG","year":"2010","unstructured":"Hanly JG, Urowitz MB, Su L, et al.. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010, 69:529-35. 10.1136\/ard.2008.106351","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2016.01.005","article-title":"Systemic lupus erythematosus: Is it one disease?","volume":"12","author":"Rivas-Larrauri F","year":"2016","unstructured":"Rivas-Larrauri F, Yamazaki-Nakashimada MA. Systemic lupus erythematosus: Is it one disease?. Reumatol Clin. 2016, 12:274-81. 10.1016\/j.reuma.2016.01.005","journal-title":"Reumatol Clin"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314541690","article-title":"Myelitis in systemic lupus erythematosus frequently manifests as longitudinal and sometimes occurs at low disease activity","volume":"23","author":"Li XY","year":"2014","unstructured":"Li XY, Xiao P, Xiao HB, Zhang LJ, Pai P, Chu P, Chan TM. Myelitis in systemic lupus erythematosus frequently manifests as longitudinal and sometimes occurs at low disease activity. Lupus. 2014, 23:1178-86. 10.1177\/0961203314541690","journal-title":"Lupus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/scsandc.2016.5","article-title":"Myelitis in systemic lupus erythematosus: clinical features, immunological profile and magnetic resonance imaging of five cases","volume":"2","author":"Hryb JP","year":"2016","unstructured":"Hryb JP, Chiganer E, Contentti EC, Di Pace JL, Lessa C, Perassolo MB. Myelitis in systemic lupus erythematosus: clinical features, immunological profile and magnetic resonance imaging of five cases. Spinal Cord Ser Cases. 2016, 2:16005. 10.1038\/scsandc.2016.5","journal-title":"Spinal Cord Ser Cases"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03208.x","article-title":"Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation","volume":"18","author":"Katsiari CG","year":"2011","unstructured":"Katsiari CG, Giavri I, Mitsikostas DD, Yiannopoulou KG, Sfikakis PP. Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. Eur J Neurol. 2011, 18:556-63. 10.1111\/j.1468-1331.2010.03208.x","journal-title":"Eur J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10429","article-title":"Longitudinally extensive transverse myelitis in a lupus-neuromyelitis optica overlap","volume":"12","author":"Tavor Y","year":"2021","unstructured":"Tavor Y, Herskovitz M, Ronen G, Balbir-Gurman A. Longitudinally extensive transverse myelitis in a lupus-neuromyelitis optica overlap. Rambam Maimonides Med J. 2021, 12:e0006. 10.5041\/RMMJ.10429","journal-title":"Rambam Maimonides Med J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3101603","article-title":"Spinal shock revisited: a four-phase model","volume":"42","author":"Ditunno JF","year":"2004","unstructured":"Ditunno JF, Little JW, Tessler A, Burns AS. Spinal shock revisited: a four-phase model. Spinal Cord. 2004, 42:383-95. 10.1038\/sj.sc.3101603","journal-title":"Spinal Cord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000963","article-title":"Metabolic and toxic myelopathies","volume":"27","author":"Parks NE","year":"2021","unstructured":"Parks NE. Metabolic and toxic myelopathies. Continuum (Minneap Minn). 2021, 27:143-62. 10.1212\/CON.0000000000000963","journal-title":"Continuum (Minneap Minn)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/art.24937","article-title":"Distinct subtypes of myelitis in systemic lupus erythematosus","volume":"60","author":"Birnbaum J","year":"2009","unstructured":"Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum. 2009, 60:3378-87. 10.1002\/art.24937","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000900","article-title":"Myelitis and other autoimmune myelopathies","volume":"27","author":"Lopez Chiriboga S","year":"2021","unstructured":"Lopez Chiriboga S, Flanagan EP. Myelitis and other autoimmune myelopathies. Continuum (Minneap Minn). 2021, 27:62-92. 10.1212\/CON.0000000000000900","journal-title":"Continuum (Minneap Minn)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31823dc535","article-title":"Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology","volume":"77","author":"Scott TF","year":"2011","unstructured":"Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology. 2011, 77:2128-34. 10.1212\/WNL.0b013e31823dc535","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon VA","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, et al.. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004, 364:2106-12. 10.1016\/S0140-6736(04)17551-X","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis","volume":"59","author":"Weinshenker BG","year":"2006","unstructured":"Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006, 59:566-9. 10.1002\/ana.20770","journal-title":"Ann Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk DM","year":"2012","unstructured":"Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012, 18:5-10. 10.1177\/1352458511431077","journal-title":"Mult Scler"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key282","article-title":"Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus","volume":"58","author":"Pr\u00f6bstel AK","year":"2019","unstructured":"Pr\u00f6bstel AK, Thanei M, Erni B, et al.. Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. Rheumatology (Oxford). 2019, 58:908-13. 10.1093\/rheumatology\/key282","journal-title":"Rheumatology (Oxford)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad N","year":"2023","unstructured":"Conrad N, Misra S, Verbakel JY, et al.. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023, 401:1878-90. 10.1016\/S0140-6736(23)00457-9","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.9.830","article-title":"Lupus-related myelopathy: report of three cases and review of the literature","volume":"55","author":"Provenzale J","year":"1992","unstructured":"Provenzale J, Bouldin TW. Lupus-related myelopathy: report of three cases and review of the literature. J Neurol Neurosurg Psychiatry. 1992, 55:830-5. 10.1136\/jnnp.55.9.830","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis A","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, et al.. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019, 78:736-45. 10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue","volume":"34","author":"Padmanabhan A","year":"2019","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N, et al.. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019, 34:171-354. 10.1002\/jca.21705","journal-title":"J Clin Apher"},{"key":"ref28","article-title":"Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome","volume":"25","author":"Mok CC","year":"1998","unstructured":"Mok CC, Lau CS, Chan EY, Wong RW. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. J Rheumatol. 1998, 25:467-73.","journal-title":"J Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.130476","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs","volume":"69","author":"Bertsias GK","year":"2010","unstructured":"Bertsias GK, Ioannidis JP, Aringer M, et al.. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010, 69:2074-82. 10.1136\/ard.2010.130476","journal-title":"Ann Rheum Dis"},{"key":"ref30","article-title":"Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis","volume":"34","author":"Tomietto P","year":"2007","unstructured":"Tomietto P, D'Agostini S, Annese V, De Vita S, Ferraccioli G. Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis. J Rheumatol. 2007, 34:588-91.","journal-title":"J Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-005-0068-1","article-title":"SLE-associated transverse myelitis successfully treated with rituximab (anti-CD20 monoclonal antibody)","volume":"26","author":"Armstrong DJ","year":"2006","unstructured":"Armstrong DJ, McCarron MT, Wright GD. SLE-associated transverse myelitis successfully treated with rituximab (anti-CD20 monoclonal antibody). Rheumatol Int. 2006, 26:771-2. 10.1007\/s00296-005-0068-1","journal-title":"Rheumatol Int"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.09.002","article-title":"Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients","volume":"39","author":"Espinosa G","year":"2010","unstructured":"Espinosa G, Mendiz\u00e1bal A, M\u00ednguez S, Ramo-Tello C, Capellades J, Oliv\u00e9 A, Cervera R. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum. 2010, 39:246-56. 10.1016\/j.semarthrit.2008.09.002","journal-title":"Semin Arthritis Rheum"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/BF00878876","article-title":"Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment","volume":"242","author":"Harisdangkul V","year":"1995","unstructured":"Harisdangkul V, Doorenbos D, Subramony SH. Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment. J Neurol. 1995, 242:326-31. 10.1007\/BF00878876","journal-title":"J Neurol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410040110","article-title":"The prognosis of acute and subacute transverse myelopathy based on early signs and symptoms","volume":"4","author":"Ropper AH","year":"1978","unstructured":"Ropper AH, Poskanzer DC. The prognosis of acute and subacute transverse myelopathy based on early signs and symptoms. Ann Neurol. 1978, 4:51-9. 10.1002\/ana.410040110","journal-title":"Ann Neurol"},{"key":"ref35","article-title":"Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies","volume":"31","author":"D'Cruz DP","year":"2004","unstructured":"D'Cruz DP, Mellor-Pita S, Joven B, et al.. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol. 2004, 31:280-5.","journal-title":"J Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/287583-longitudinally-extensive-transverse-myelitis-in-a-patient-with-systemic-lupus-erythematosus-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T02:55:56Z","timestamp":1725159356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/287583-longitudinally-extensive-transverse-myelitis-in-a-patient-with-systemic-lupus-erythematosus-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.68337","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,31]]}}}